<code id='FA31E16EC2'></code><style id='FA31E16EC2'></style>
    • <acronym id='FA31E16EC2'></acronym>
      <center id='FA31E16EC2'><center id='FA31E16EC2'><tfoot id='FA31E16EC2'></tfoot></center><abbr id='FA31E16EC2'><dir id='FA31E16EC2'><tfoot id='FA31E16EC2'></tfoot><noframes id='FA31E16EC2'>

    • <optgroup id='FA31E16EC2'><strike id='FA31E16EC2'><sup id='FA31E16EC2'></sup></strike><code id='FA31E16EC2'></code></optgroup>
        1. <b id='FA31E16EC2'><label id='FA31E16EC2'><select id='FA31E16EC2'><dt id='FA31E16EC2'><span id='FA31E16EC2'></span></dt></select></label></b><u id='FA31E16EC2'></u>
          <i id='FA31E16EC2'><strike id='FA31E16EC2'><tt id='FA31E16EC2'><pre id='FA31E16EC2'></pre></tt></strike></i>

          explore

          explore

          author:leisure time    Page View:422
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Oak Street deal isn't the answer to health care's woes
          Oak Street deal isn't the answer to health care's woes

          JustinSullivan/GettyImagesCVSHealth’sacquisitionofOakStreetHealth,aMedicare-focusedprimarycareprovid

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          Oak Street deal isn't the answer to health care's woes

          JustinSullivan/GettyImagesCVSHealth’sacquisitionofOakStreetHealth,aMedicare-focusedprimarycareprovid